NASDAQ:ICLR - ICON Public Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $282.67
  • Forecasted Upside: 21.93 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
▼ -1.29 (-0.55%)

This chart shows the closing price for ICLR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ICON Public Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ICLR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ICLR

Analyst Price Target is $282.67
▲ +21.93% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for ICON Public in the last 3 months. The average price target is $282.67, with a high forecast of $320.00 and a low forecast of $245.00. The average price target represents a 21.93% upside from the last price of $231.83.

This chart shows the closing price for ICLR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 contributing investment analysts is to buy stock in ICON Public. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/29/2022Deutsche Bank AktiengesellschaftBoost Price Target$285.00 ➝ $295.00Low
7/28/2022William BlairReiterated RatingOutperformLow
7/14/2022Deutsche Bank AktiengesellschaftLower Price TargetBuy$310.00 ➝ $285.00N/A
7/13/2022BarclaysLower Price TargetEqual Weight$250.00 ➝ $245.00N/A
7/8/2022CitigroupLower Price TargetBuy$315.00 ➝ $290.00N/A
5/23/2022GuggenheimInitiated CoverageBuy$285.00Low
5/13/2022Robert W. BairdReiterated RatingBuy$285.00Low
4/25/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$280.00 ➝ $250.00High
4/11/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$234.00 ➝ $310.00Medium
3/7/2022MizuhoLower Price TargetBuy$315.00 ➝ $272.00Medium
2/25/2022Deutsche Bank AktiengesellschaftLower Price TargetHold$287.00 ➝ $235.00Medium
2/23/2022BarclaysLower Price TargetEqual Weight$285.00 ➝ $255.00Low
2/23/2022CitigroupLower Price TargetBuy$340.00 ➝ $315.00Low
1/27/2022BarclaysLower Price TargetEqual Weight$315.00 ➝ $285.00Medium
11/16/2021Deutsche Bank AktiengesellschaftBoost Price TargetHold$234.00 ➝ $287.00Low
11/5/2021BarclaysBoost Price TargetEqual Weight$240.00 ➝ $315.00Medium
11/5/2021MizuhoBoost Price TargetBuy$242.00 ➝ $315.00Medium
9/27/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$230.00 ➝ $320.00High
9/14/2021Jefferies Financial GroupBoost Price TargetBuy$276.00 ➝ $302.00High
7/26/2021Deutsche Bank AktiengesellschaftBoost Price TargetHold$212.00 ➝ $234.00Low
7/23/2021CitigroupUpgradeNeutral ➝ Buy$260.00Medium
7/23/2021Wells Fargo & CompanyBoost Price TargetPositive ➝ Overweight$250.00 ➝ $280.00High
7/23/2021Robert W. BairdBoost Price TargetOutperform$260.00 ➝ $265.00High
7/20/2021Credit Suisse GroupBoost Price TargetOutperform$245.00 ➝ $250.00Low
7/14/2021CitigroupInitiated CoverageNeutral$220.00Low
5/3/2021MizuhoBoost Price TargetBuy$217.00 ➝ $242.00Low
4/29/2021Credit Suisse GroupBoost Price TargetOutperform$240.00 ➝ $245.00Low
4/29/2021Jefferies Financial GroupBoost Price TargetBuy$256.00 ➝ $267.00Low
4/13/2021Bank of AmericaInitiated CoverageNeutralMedium
4/1/2021Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$200.00 ➝ $235.00Medium
3/8/2021BarclaysInitiated CoverageEqual Weight$200.00N/A
3/8/2021Robert W. BairdUpgradeNeutral ➝ Outperform$215.00Low
3/2/2021BarclaysInitiated CoverageEqual Weight$200.00High
3/1/2021UBS GroupUpgradeNeutral ➝ Buy$207.00 ➝ $232.00Low
2/26/2021Truist FinancialUpgradeHold ➝ Buy$280.00High
2/25/2021Deutsche Bank AktiengesellschaftBoost Price TargetHold$179.00 ➝ $208.00Medium
10/23/2020Deutsche Bank AktiengesellschaftBoost Price TargetHold$170.00 ➝ $179.00Medium
10/23/2020MizuhoBoost Price TargetBuy$195.00 ➝ $217.00Medium
10/22/2020Credit Suisse GroupBoost Price TargetOutperform$230.00 ➝ $235.00Medium
7/27/2020UBS GroupBoost Price TargetNeutral$188.00 ➝ $194.00Low
7/27/2020Deutsche Bank AktiengesellschaftBoost Price TargetHold$135.00 ➝ $170.00Low
7/27/2020MizuhoBoost Price TargetBuy$170.00 ➝ $195.00Low
7/24/2020Bank of AmericaDowngradeBuy ➝ NeutralLow
7/24/2020Jefferies Financial GroupBoost Price TargetBuy$184.00 ➝ $220.00Low
7/23/2020Credit Suisse GroupBoost Price TargetOutperform$181.00 ➝ $205.00High
4/27/2020SunTrust BanksBoost Price TargetHold$131.00 ➝ $157.00Medium
4/24/2020Deutsche Bank AktiengesellschaftLower Price TargetHold$169.00 ➝ $135.00Medium
4/23/2020Credit Suisse GroupLower Price TargetOutperform$187.00 ➝ $181.00High
4/23/2020BarclaysBoost Price TargetOverweight$170.00 ➝ $180.00High
4/20/2020Robert W. BairdDowngradeOutperform ➝ Neutral$151.00Low
4/9/2020CitigroupLower Price TargetNeutral$185.00 ➝ $160.00Medium
4/3/2020MizuhoLower Price TargetBuy$180.00 ➝ $154.00Low
3/30/2020Wells Fargo & CompanyLower Price TargetEqual Weight$180.00 ➝ $140.00Low
3/26/2020BarclaysUpgradeEqual Weight ➝ Overweight$182.00 ➝ $170.00High
3/23/2020Jefferies Financial GroupLower Price TargetBuy$180.00 ➝ $146.00High
3/17/2020SunTrust BanksLower Price TargetHold$182.00 ➝ $131.00Medium
3/2/2020Deutsche Bank AktiengesellschaftInitiated CoverageHold$169.00High
2/21/2020UBS GroupBoost Price TargetNeutral$174.00 ➝ $182.00Medium
2/20/2020BarclaysBoost Price TargetEqual Weight$168.00 ➝ $182.00High
2/20/2020MizuhoReiterated RatingBuy$179.00 ➝ $194.00High
1/27/2020SunTrust BanksDowngradeBuy ➝ Hold$170.00 ➝ $182.00Medium
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$180.00Low
1/6/2020CitigroupInitiated CoverageNeutral$185.00Low
10/28/2019Credit Suisse GroupReiterated RatingBuy$160.00Low
10/25/2019UBS GroupSet Price TargetHold$160.00N/A
10/18/2019UBS GroupLower Price TargetNeutral$171.00 ➝ $158.00Low
8/8/2019KeyCorpBoost Price TargetOverweight$157.00 ➝ $165.00Medium
7/26/2019UBS GroupUpgradeSell ➝ Neutral$135.00 ➝ $171.00Low
7/25/2019MizuhoBoost Price TargetBuy$160.00 ➝ $170.00High
6/11/2019MizuhoBoost Price TargetBuy$154.00 ➝ $160.00Low
4/17/2019BarclaysReiterated RatingHold$154.00High
4/2/2019Wolfe ResearchInitiated CoverageOutperformLow
3/18/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$140.00 ➝ $148.00Low
2/25/2019SunTrust BanksReiterated RatingBuy$161.00Medium
2/21/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$130.00 ➝ $140.00Low
1/25/2019MizuhoUpgradeNeutral ➝ Buy$146.00 ➝ $150.00Medium
12/14/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy$168.00Medium
10/27/2018UBS GroupSet Price TargetSell$136.00Medium
10/26/2018Evercore ISIUpgradeIn-Line ➝ OutperformMedium
10/9/2018UBS GroupInitiated CoverageSell ➝ Sell$145.00Medium
9/11/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$154.00 ➝ $157.00Low
9/11/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$152.00 ➝ $157.00Low
8/6/2018MizuhoSet Price TargetHold$146.00Medium
7/26/2018Robert W. BairdReiterated RatingBuy$154.00High
7/26/2018SunTrust BanksBoost Price TargetBuy$153.00High
6/19/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$131.00 ➝ $144.00Medium
6/18/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$130.00 ➝ $152.00Low
6/1/2018Jefferies Financial GroupBoost Price TargetBuy$150.00Medium
2/16/2018Credit Suisse GroupUpgradeBuy$131.00Low
2/15/2018MizuhoReiterated RatingNeutral ➝ Neutral$109.00 ➝ $114.00Low
1/24/2018MizuhoSet Price TargetHold$109.00Low
1/22/2018SunTrust BanksReiterated RatingBuy$133.00Low
1/18/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$126.00High
1/11/2018KeyCorpReiterated RatingBuy$130.00Medium
11/13/2017KeyCorpReiterated RatingOverweight$115.00 ➝ $125.00N/A
10/29/2017SunTrust BanksReiterated RatingReduce ➝ Buy$138.00N/A
10/27/2017BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$108.00 ➝ $120.00N/A
10/16/2017Credit Suisse GroupReiterated RatingOutperform$105.00 ➝ $120.00N/A
10/12/2017Robert W. BairdReiterated RatingBuy$123.00N/A
10/9/2017Jefferies Financial GroupBoost Price TargetBuy$122.00 ➝ $132.00N/A
9/12/2017Jefferies Financial GroupReiterated RatingBuy$122.00Low
9/11/2017Bank of AmericaInitiated CoverageBuy ➝ Buy$128.00Low
(Data available from 8/9/2017 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 7 positive mentions
  • 6 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 6 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
ICON Public logo
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $231.83
Low: $231.68
High: $237.73

50 Day Range

MA: $218.81
Low: $197.30
High: $241.25

52 Week Range

Now: $231.83
Low: $196.34
High: $313.00


407,167 shs

Average Volume

467,869 shs

Market Capitalization

$18.87 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of ICON Public?

The following Wall Street research analysts have issued reports on ICON Public in the last year: Barclays PLC, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Guggenheim, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Robert W. Baird,, TheStreet, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for ICLR.

What is the current price target for ICON Public?

9 Wall Street analysts have set twelve-month price targets for ICON Public in the last year. Their average twelve-month price target is $282.67, suggesting a possible upside of 21.9%. JPMorgan Chase & Co. has the highest price target set, predicting ICLR will reach $320.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $245.00 for ICON Public in the next year.
View the latest price targets for ICLR.

What is the current consensus analyst rating for ICON Public?

ICON Public currently has 2 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ICLR will outperform the market and that investors should add to their positions of ICON Public.
View the latest ratings for ICLR.

What other companies compete with ICON Public?

How do I contact ICON Public's investor relations team?

ICON Public's physical mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company's listed phone number is (531) 291-2000. The official website for ICON Public is Learn More about contacing ICON Public investor relations.